tyra-300
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 22, 2022 (NCT05544552)
Timeline
Indications
Studied for
- Achondroplasia · Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Mutation · Phase 2
- Neoplasms · Phase 1/Phase 2
- Receptor, Fibroblast Growth Factor, Type 3 · Phase 2
- Receptors, Fibroblast Growth Factor · Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Urologic Neoplasms · Phase 1/Phase 2
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07265947 | Phase 2 | Dec 31, 2025 | Tyra Biosciences, Inc |
| NCT06995677 | Phase 2 | Jun 27, 2025 | Tyra Biosciences, Inc |
| NCT06842355 | Phase 2 | Mar 31, 2025 | Tyra Biosciences, Inc |
| NCT06006702 | Phase 1 | Oct 16, 2023 | Tyra Biosciences, Inc |
| NCT05544552 | Phase 1/Phase 2 (Phase 2) | Nov 22, 2022 | Tyra Biosciences, Inc |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tyra Biosciences, Inc | For profit | 5 | 5 | 2 | 2022 |
1 organizations
Page 1 / 1